The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...

In addition to requests for double-digit premium increases, Blue Cross Blue Shield of Vermont is also cutting back on coverage of popular weight-loss drugs on some plans.

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

That decision by one of the nation's largest PBMs triggered fears of a price war in the weight loss drug market and concerns that Zepbound's sales momentum could stall. Shares of Eli Lilly plunged ...

President Donald Trump signed an executive order May 12 directing drugmakers to sell medicines in the U.S. at prices similar to those offered in other wealthy countries, or face penalties and ...

Major benchmarks are down this year amid concerns about import tariffs and their impact on ... and gives Lilly more firepower as it seeks to gain wider insurance coverage in an obesity drug market ...

Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge Eli Lilly ... allaying investor concerns about the sector after bellwether UnitedHealth's disappointing financial results ...